BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25623745)

  • 1. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
    Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
    J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved prediction of long-term, other cause mortality in men with prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
    J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
    Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy.
    Chen MS; Howard LE; Stock S; Dolgner A; Freedland SJ; Aronson W; Terris M; Klaassen Z; Kane C; Amling C; Cooperberg M; Daskivich TJ
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):715-721. PubMed ID: 35668181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of an Age-adjusted Prostate Cancer-Specific Comorbidity Index.
    Froehner M; Koch R; Hübler M; Wirth MP
    Eur Urol; 2016 May; 69(5):764-6. PubMed ID: 26558839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbidity and competing risks for mortality in men with prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
    Cancer; 2011 Oct; 117(20):4642-50. PubMed ID: 21480201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration.
    Soerensen SJC; Thomas IC; Schmidt B; Daskivich TJ; Skolarus TA; Jackson C; Osborne TF; Chertow GM; Brooks JD; Rehkopf DH; Leppert JT
    Urology; 2021 Sep; 155():70-76. PubMed ID: 34139251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
    Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
    Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
    J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
    Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
    Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful external validation of a model to predict other cause mortality in localized prostate cancer.
    Kent M; Penson DF; Albertsen PC; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Ehdaie B; Scardino PT; Vickers AJ
    BMC Med; 2016 Feb; 14():25. PubMed ID: 26860993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.